[ad_1]
The COVID-19 vaccine developed by the University of Oxford and the AstraZeneca company elicits a robust immune response in the elderly, the category most at risk, the Financial Times wrote on Monday, citing preliminary results, Reuters reports, cited by Agerpres.
The vaccine triggers the production of protective antibodies and T cells in older age groups, according to the Financial Times, which cites two sources with knowledge of the discovery, a result that encourages researchers to seek evidence that the product will protect the elderly from serious illness or death from the virus.
Details of the find will be published soon in a medical journal, the Financial Times added.
The results coincide with data published in July, according to which the vaccine generated “robust immune responses” in a group of healthy adults, between 18 and 55 years old, the newspaper reported, citing sources close to the results of the so-called immunogenicity tests. . .
However, the Financial Times cautioned that positive immunogenicity tests do not guarantee that the vaccine will ultimately prove safe and effective in the elderly.
AstraZeneca, which is developing the vaccine with researchers at the University of Oxford, is considered a leader in the race to develop a vaccine to protect against COVID-19.
Oxford and AstraZeneca did not immediately respond to Reuters’ request for comment.
One of the most important candidate vaccines against coronavirus, called AZD1222 or ChAdOx1 nCoV-19, was developed by scientists at the University of Oxford, and AstraZeneca obtained its production license in April, taking on the task of continuing clinical trials and production.
AstraZeneca has resumed clinical trials of the vaccine in the United States after receiving approval from US regulators, the company announced Friday.
It is a viral vector vaccine (VRV), which uses a weakened version of a virus that causes the common cold in chimpanzees, modified with genetic instructions to trigger an immune response against COVID-19.
Editing: Monica Bonea
